Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Update

Avenue Therapeutics, Inc. (NASDAQ:ATXI) saw a significant increase in short interest in September. As of September 30th, there was short interest totalling 31,500 shares, an increase of 107.2% from the September 15th total of 15,200 shares. Based on an average daily trading volume, of 45,200 shares, the short-interest ratio is currently 0.7 days. Approximately 2.3% of the company’s shares are sold short.

Hedge Funds Weigh In On Avenue Therapeutics

A hedge fund recently bought a new stake in Avenue Therapeutics stock. Armistice Capital LLC purchased a new stake in shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 75,000 shares of the company’s stock, valued at approximately $262,000. Armistice Capital LLC owned approximately 7.97% of Avenue Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 17.34% of the company’s stock.

Avenue Therapeutics Trading Up 2.0 %

Avenue Therapeutics stock traded up $0.04 during trading hours on Friday, hitting $2.06. 7,020 shares of the stock traded hands, compared to its average volume of 58,539. Avenue Therapeutics has a one year low of $1.90 and a one year high of $45.75. The firm’s 50-day moving average price is $2.54 and its two-hundred day moving average price is $4.35. The company has a market cap of $2.95 million, a PE ratio of 0.08 and a beta of -0.17.

Avenue Therapeutics (NASDAQ:ATXI) last issued its quarterly earnings results on Friday, August 9th. The company reported ($6.43) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($5.38).

About Avenue Therapeutics

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.